Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.52 USD | +3.20% | +11.33% | -9.78% |
May. 30 | Stifel Starts Abeona Therapeutics With Buy Rating, $21 Price Target | MT |
May. 16 | Cantor Fitzgerald Adjusts Price Target on Abeona Therapeutics to $21 From $36, Maintains Overweight Rating | MT |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 16.54M | Capitalization | 186M |
---|---|---|---|---|---|
Net income 2024 * | -70M | Net income 2025 * | -65M | EV / Sales 2024 * | - |
Net cash position 2024 * | 66.3M | Net Debt 2025 * | 7.4M | EV / Sales 2025 * | 11.7 x |
P/E ratio 2024 * |
-2.47
x | P/E ratio 2025 * |
-2.94
x | Employees | 84 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.62% |
Latest transcript on Abeona Therapeutics Inc.
1 day | +3.20% | ||
1 week | +11.33% | ||
Current month | +3.20% | ||
1 month | +11.06% | ||
3 months | -42.13% | ||
6 months | -3.00% | ||
Current year | -9.78% |
Managers | Title | Age | Since |
---|---|---|---|
Vishwas Seshadri
CEO | Chief Executive Officer | 48 | 21-05-31 |
Michael Amoroso
CHM | Chairman | 46 | 20-07-08 |
Joseph Vazzano
DFI | Director of Finance/CFO | 40 | 22-03-13 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mark Alvino
BRD | Director/Board Member | 56 | 06-02-28 |
Faith Charles
BRD | Director/Board Member | 62 | 21-03-24 |
Leila Alland
BRD | Director/Board Member | 61 | 21-04-18 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-03 | 4.52 | +3.20% | 782,148 |
24-05-31 | 4.38 | +4.04% | 443,061 |
24-05-30 | 4.21 | +3.69% | 832,256 |
24-05-29 | 4.06 | -0.98% | 380,753 |
Delayed Quote Nasdaq, June 03, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.78% | 180M | |
+48.64% | 54.63B | |
-6.44% | 39.92B | |
+37.07% | 38.82B | |
+14.28% | 26.86B | |
-11.17% | 26.22B | |
-21.40% | 18.78B | |
+25.64% | 12.21B | |
+0.96% | 12.16B | |
+27.04% | 11.94B |
- Stock Market
- Equities
- ABEO Stock